Loading
A phase 2 trial of Zongertinib in advanced solid tumours, run by Boehringer Ingelheim, now recruiting.
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations is a phase 2 interventional study registered as NCT06581432 by Boehringer Ingelheim, with 588 participants planned, started 2024-10-11 and due to reach its primary completion in 2028-11-30. Interventions recorded: Zongertinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zongertinib, Boehringer Ingelheim, Small-molecule kinase inhibitors and the tag pipeline.
Shares Zongertinib, Boehringer Ingelheim, Small-molecule kinase inhibitors and the tag pipeline.
Shares Boehringer Ingelheim, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/